Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A DSM-IV diagnosis of schizophrenia (disorganized, catatonic, paranoid, residual, or undifferentiated type) for at least 1 year before the screening evaluation~* a total PANSS score of 70 to 120 at screening and baseline (pre-treatment) evaluations~* a body mass index (BMI \[weight (kilograms)\]/\[height (meters)\]²) of more than 17.0 kg/m²~Exclusion Criteria:~* A primary active DSM-IV Axis I diagnosis other than schizophrenia~* a decrease of 25% or more in the total PANSS score between screening and baseline evaluations~* a DSM-IV diagnosis of active substance dependence within 3 months of screening evaluation~* a history of treatment resistance as defined by failure to respond to 2 adequate trials of different antipsychotic medications~* a woman who is pregnant, breast-feeding, or planning to become pregnant during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).